SHARE is Here for You

Our lives have changed so much in the weeks since the coronavirus pandemic emerged. But some things remain the same. SHARE is here for you, no matter your situation.

Outreach Ambassador Open House 2019

Please join us for an open house to learn about SHARE’s Ambassador Program and the opportunity to become an Ambassador! SHARE Ambassadors are breast and ovarian cancer survivors or caregivers trained to educate underserved Latino, African-American and Caribbean communities about these diseases.

Join SHARE’s Young Professionals Advisory Board!

SHARE is forming an Advisory Board to offer an opportunity for young people to support SHARE's work. Join us for an informational session on August 13 at 6:30pm at SHARE's office, 165 W 46th St., Suite 706 to learn more. Drinks and bites provided. RSVP to our Administrative Manager.

Treating Endocrine-Resistant Metastatic Breast Cancer

In September, the FDA approved amebaciclib (Verzenio), the latest drug to treat endocrine resistant metastatic breast cancer (MBC). In combination with fulvestrant (Faslodex), the results of the phase III, Monarch 2 trial showed an improvement in progression free survival (PFS). All the patients in the trial were hormone receptor positive and HER2 negative, as are all the enrollees in the trials noted here.

Update on TAPUR Study

At its annual meeting this year in June, the American Society of Clinical Oncology (ASCO) gave patient advocates an update on the TAPUR clinical trial, which is its first trial. The trial was rolled out about two years ago.

The TAPUR trial (Targeted Agent and Profiling Utilization Registry) allows us to obtain FDA-approved drugs free-of-charge by cutting out the red tape when we are no longer benefiting from any standard treatment.